Komori
Astellas Pharma (4503) · InitiativeAchieved

Development discontinued for FX-322

First written in FY2023. 1 of 1 entries say "Achieved", first in FY2023. Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of FX-322 (drug for sensorineural hearing loss) developmentA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「2023年４月　感音難聴を対象として第Ⅱ相段階にあったFX-322の開発を中止したことを公表しました。」

    Frequency Therapeutics社から導入したFX-322について、感音難聴を対象とする第Ⅱ相開発を中止し、86億円の無形資産減損損失を計上した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.